- Home
- ONCY vs BUDA Comparison
ONCY vs BUDA Comparison
Compare ONCY & BUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCY | BUDA |
|---|---|---|
| Founded | 1998 | 2013 |
| Country | Canada | United States |
| Employees | N/A | 39 |
| Industry | Pharmaceuticals and Biotechnology | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.7M | 91.7M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONCY | BUDA |
|---|---|---|
| Price | $0.94 | $8.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $7.33 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 1.6M | 12.8K |
| Earning Date | 05-08-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,505.00 | N/A |
| P/E Ratio | ★ N/A | $24.42 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $6.25 |
| 52 Week High | $1.51 | $10.70 |
Technical Indicators
Market Signals| Indicator | ONCY | BUDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 49.64 |
| Support Level | $0.90 | $8.21 |
| Resistance Level | $1.06 | $10.42 |
| Average True Range (ATR) | 0.06 | 0.80 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 62.80 | 71.34 |
Price Performance
Historical ComparisonAbout ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
About BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never heat-treated, pasteurized, never HPP- processed, never UV- treated and always cold.